[go: up one dir, main page]

DE60031504D1 - Fluticasonpropionat arzneizubereitung - Google Patents

Fluticasonpropionat arzneizubereitung

Info

Publication number
DE60031504D1
DE60031504D1 DE60031504T DE60031504T DE60031504D1 DE 60031504 D1 DE60031504 D1 DE 60031504D1 DE 60031504 T DE60031504 T DE 60031504T DE 60031504 T DE60031504 T DE 60031504T DE 60031504 D1 DE60031504 D1 DE 60031504D1
Authority
DE
Germany
Prior art keywords
fluticasonpropionate
drug preparation
formulation
fluticasone propionate
hydrofluoroalkane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60031504T
Other languages
English (en)
Other versions
DE60031504T2 (de
Inventor
Alan Leslie Cripps
Paul Johnson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27255761&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60031504(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9921396.9A external-priority patent/GB9921396D0/en
Priority claimed from GB0014451A external-priority patent/GB0014451D0/en
Priority claimed from GB0018654A external-priority patent/GB0018654D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of DE60031504D1 publication Critical patent/DE60031504D1/de
Application granted granted Critical
Publication of DE60031504T2 publication Critical patent/DE60031504T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
DE60031504T 1999-09-11 2000-09-11 Fluticasonpropionat arzneizubereitung Expired - Lifetime DE60031504T2 (de)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB9921396 1999-09-11
GBGB9921396.9A GB9921396D0 (en) 1999-09-11 1999-09-11 Pharmaceutical formulation
GB0014451A GB0014451D0 (en) 2000-06-13 2000-06-13 Pharmaceutical formulation
GB0014451 2000-06-13
GB0018654A GB0018654D0 (en) 2000-07-28 2000-07-28 Pharmaceutical formulation
GB0018654 2000-07-28
PCT/GB2000/003471 WO2001019342A2 (en) 1999-09-11 2000-09-11 Pharmaceutical formulation of fluticasone propionate

Publications (2)

Publication Number Publication Date
DE60031504D1 true DE60031504D1 (de) 2006-12-07
DE60031504T2 DE60031504T2 (de) 2007-04-05

Family

ID=27255761

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60031504T Expired - Lifetime DE60031504T2 (de) 1999-09-11 2000-09-11 Fluticasonpropionat arzneizubereitung

Country Status (12)

Country Link
US (4) US6479035B1 (de)
EP (1) EP1143930B8 (de)
JP (1) JP2003509359A (de)
AT (1) ATE343374T1 (de)
AU (1) AU7026800A (de)
CA (1) CA2317999C (de)
DE (1) DE60031504T2 (de)
ES (1) ES2274803T3 (de)
FR (4) FR2798290B1 (de)
GB (1) GB2354007B (de)
IT (1) IT1317904B1 (de)
WO (1) WO2001019342A2 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9814717D0 (en) * 1998-02-23 1998-09-02 Bespak Plc Improvements in drug delivery devices
GB2354007B (en) * 1999-09-11 2003-10-22 Glaxo Group Ltd Pharmaceutical formulation of fluticasone propionate
WO2001047493A1 (en) * 1999-12-24 2001-07-05 Glaxo Group Limited Pharmaceutical aerosol formulation of salmeterol and fluticasone propionate
IT1317720B1 (it) * 2000-01-07 2003-07-15 Chiesi Farma Spa Dispositivo per la somministrazione di aerosol dosati pressurizzati inpropellenti idrofluoroalcani.
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
JP5082033B2 (ja) 2001-12-21 2012-11-28 エグゼリクシス パテント カンパニー エルエルシー Ｌｘｒのモジュレーター
EP1321159A1 (de) * 2001-12-21 2003-06-25 CHIESI FARMACEUTICI S.p.A. Betätigungsvorrichtung für Druckdosierinhalator mit lasergebohrten Löchern
US7482366B2 (en) 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
PT3494995T (pt) * 2002-03-01 2020-03-30 Chiesi Farm Spa Formulação superfina de formoterol
EP1340492A1 (de) * 2002-03-01 2003-09-03 CHIESI FARMACEUTICI S.p.A. Aerosolformulierungen zur pulmonalen Verabreichung von Arzneimitteln mit systemischer Wirkung
US20040265238A1 (en) * 2003-06-27 2004-12-30 Imtiaz Chaudry Inhalable formulations for treating pulmonary hypertension and methods of using same
TWI359675B (en) 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
US8367734B1 (en) 2005-08-11 2013-02-05 Amphastar Pharmaceuticals Inc. Stable epinephrine suspension formulation with high inhalation delivery efficiency
WO2007064932A2 (en) * 2005-12-02 2007-06-07 Bayer Healthcare Llc. Pyrrolotriazine derivatives useful for treating cancer through inhibition of aurora kinase
GB0712454D0 (en) * 2007-06-27 2007-08-08 Generics Uk Ltd Pharmaceutical compositions
EP3403654B1 (de) 2009-10-01 2019-07-31 Adare Development I, L.P. Oral verabreichte corticosteroid-zusammensetzungen
TWI399202B (zh) 2011-03-17 2013-06-21 Intech Biopharm Ltd 製備用於治療呼吸道疾病之定量噴霧吸入劑的製程方法
GB201108039D0 (en) * 2011-05-13 2011-06-29 Mexichem Amanco Holding Sa Compositions
CN102379846B (zh) * 2011-10-21 2014-07-02 江苏长风药业有限公司 以氢氟烷烃和聚乙二醇为辅料氟替卡松丙酸酯气雾剂制剂
ES2727474T3 (es) 2012-05-08 2019-10-16 Nicox Ophthalmics Inc Nanocristales de propionato de fluticasona
US8765725B2 (en) 2012-05-08 2014-07-01 Aciex Therapeutics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
US9815865B2 (en) 2013-01-07 2017-11-14 Nicox Ophthalmics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
WO2015034678A2 (en) 2013-09-06 2015-03-12 Aptalis Pharmatech, Inc. Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis
TWI777515B (zh) 2016-08-18 2022-09-11 美商愛戴爾製藥股份有限公司 治療嗜伊紅性食道炎之方法
EP3797964B1 (de) 2019-09-26 2023-06-07 Presspart Manufacturing S.A. Spritzgiesswerkzeug für inhalator abgemessener dosen
WO2021216779A1 (en) * 2020-04-21 2021-10-28 Amphastar Pharmaceuticals, Inc. Anti-viral pharmaceutical formulations administered via devices for lung targeted delivery

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE629985A (de) * 1962-11-29
CH634480A5 (de) * 1977-11-25 1983-02-15 Schwarzkopf Gmbh Hans Unter druck stehendes aerosolpraeparat.
DE2949933A1 (de) 1979-12-12 1981-06-19 Wabco Fahrzeugbremsen Gmbh, 3000 Hannover Vorrichtung zum verhindern von schlingerbewegungen eines anhaengers
GB8828477D0 (en) * 1988-12-06 1989-01-05 Riker Laboratories Inc Medical aerosol formulations
IL95590A (en) 1989-09-08 1996-06-18 Glaxo Group Ltd Medicinal preparations containing Salmetrol and Pluticasone Propionate
GB2235627B (en) 1989-09-08 1993-09-01 Glaxo Group Ltd Inhalation medicaments for treating respiratory disorders
US5270305A (en) * 1989-09-08 1993-12-14 Glaxo Group Limited Medicaments
US5919827A (en) 1990-07-11 1999-07-06 Sepracor Inc. Method for treating asthma using optically pure R(-) salmeterol
WO1992006675A1 (en) 1990-10-18 1992-04-30 Minnesota Mining And Manufacturing Company Aerosol formulation comprising beclomethasone 17,21 dipropionate
MX9203481A (es) * 1990-10-18 1992-07-01 Minnesota Mining & Mfg Formulaciones.
US5736124A (en) * 1991-12-12 1998-04-07 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicament
DK0616525T3 (da) 1991-12-12 1996-01-08 Glaxo Group Ltd Medikamenter
US5658549A (en) * 1991-12-12 1997-08-19 Glaxo Group Limited Aerosol formulations containing propellant 134a and fluticasone propionate
US5683676A (en) 1991-12-12 1997-11-04 Glaxo Group Limited Canister containing aerosol formulations containing P134a and particulate medicaments
IL104068A (en) * 1991-12-12 1998-10-30 Glaxo Group Ltd Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant
ES2129117T3 (es) 1992-12-09 1999-06-01 Boehringer Ingelheim Pharma Formulaciones en disolucion en forma de aerosol medicinales estabilizadas.
GB9313650D0 (en) * 1993-07-01 1993-08-18 Glaxo Group Ltd Method and apparatus for the formation of particles
DE4446891A1 (de) * 1994-12-27 1996-07-04 Falk Pharma Gmbh Stabile wäßrige Budesonid-Lösung
AP960A (en) 1995-04-14 2001-04-20 Glaxo Wellcome Inc Metered dose inhaler for fluticasone propionate.
NZ336049A (en) * 1996-12-04 2000-09-29 Bioglan Ireland R & D Ltd Aersol device for administering pharmaceutical active agents in a solution of propellant, carrier and valve means for delivering this to the exterior of the container
DK1014943T3 (da) * 1997-02-05 2002-10-14 Jago Res Ag Medicinske aerosolformuleringer
GB2326334A (en) 1997-06-13 1998-12-23 Chiesi Farma Spa Pharmaceutical aerosol compositions
US6309623B1 (en) * 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
GB2332372B (en) * 1997-12-08 2002-08-14 Minnesota Mining & Mfg Pharmaceutical aerosol compositions
KR20010072581A (ko) 1998-04-30 2001-07-31 캐롤린 에이. 베이츠 약품 에어로졸용 복용량 계량형 밸브
ATE253896T1 (de) 1998-06-18 2003-11-15 Boehringer Ingelheim Pharma Zwei oder mehrere wirkstoffe enthaltende pharmazeutische aerosolformulierungen
US6241969B1 (en) * 1998-06-26 2001-06-05 Elan Corporation Plc Aqueous compositions containing corticosteroids for nasal and pulmonary delivery
US6585958B1 (en) * 1998-07-24 2003-07-01 Jago Research Ag Medicinal aerosol formulations
IT1303788B1 (it) 1998-11-25 2001-02-23 Chiesi Farma Spa Formulazioni di aerosol medicinali.
US6004537A (en) 1998-12-18 1999-12-21 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol
GB9903759D0 (en) 1999-02-18 1999-04-14 Novartis Ag Organic compounds
US6231519B1 (en) * 1999-05-04 2001-05-15 Nokia Corporation Method and apparatus for providing air quality analysis based on human reactions and clustering methods
US6315985B1 (en) * 1999-06-18 2001-11-13 3M Innovative Properties Company C-17/21 OH 20-ketosteroid solution aerosol products with enhanced chemical stability
GB2354007B (en) * 1999-09-11 2003-10-22 Glaxo Group Ltd Pharmaceutical formulation of fluticasone propionate
ATE286716T1 (de) 1999-11-23 2005-01-15 Glaxo Group Ltd Pharmazeutische formulierungen enthaltend salmeterol
GB0002798D0 (en) 2000-02-09 2000-03-29 Glaxo Group Ltd Actuator nozzle for metered dose inhaler

Also Published As

Publication number Publication date
ITRM20000491A0 (it) 2000-09-11
GB0022222D0 (en) 2000-10-25
CA2317999C (en) 2004-11-09
US6630129B2 (en) 2003-10-07
ATE343374T1 (de) 2006-11-15
EP1143930A3 (de) 2002-09-11
GB2354007A (en) 2001-03-14
US6479035B1 (en) 2002-11-12
AU7026800A (en) 2001-04-17
FR2848453A1 (fr) 2004-06-18
US20040157815A1 (en) 2004-08-12
FR2820322A1 (fr) 2002-08-09
FR2798290B1 (fr) 2003-09-12
FR2820322B1 (fr) 2005-03-11
GB2354007B (en) 2003-10-22
US7220403B2 (en) 2007-05-22
IT1317904B1 (it) 2003-07-15
WO2001019342A2 (en) 2001-03-22
WO2001019342A3 (en) 2001-08-09
DE60031504T2 (de) 2007-04-05
FR2843882A1 (fr) 2004-03-05
US20040037783A1 (en) 2004-02-26
ITRM20000491A1 (it) 2002-03-11
FR2848453B1 (fr) 2010-09-03
FR2798290A1 (fr) 2001-03-16
EP1143930A2 (de) 2001-10-17
EP1143930B1 (de) 2006-10-25
FR2843882B1 (fr) 2011-04-22
ES2274803T3 (es) 2007-06-01
CA2317999A1 (en) 2001-03-11
US20030086876A1 (en) 2003-05-08
JP2003509359A (ja) 2003-03-11
EP1143930B8 (de) 2008-03-19

Similar Documents

Publication Publication Date Title
DE60031504D1 (de) Fluticasonpropionat arzneizubereitung
ATE291898T1 (de) Pharmazeutische aerosol formulierung enthaltend salmeterol und fluticason
PT1037604E (pt) Composicoes farmaceuticas de aerossol
US6136294C1 (en) Amino acid stabilized medical aerosol formulation
DE60308997D1 (de) Formulierungen zur inhalation
MXPA03000442A (es) Una formulacion medicinal en aerosol.
NZ298169A (en) Aerosol drug formulation; comprises hydrofluoroalkane propellant, medicament for inhalation and a surfactant
EP1135173A4 (de) Medikamenthaltige zusammensetzung in aerosolform
DK0918507T3 (da) Aerosolformuleringer
GB0016876D0 (en) Novel formulation
MXPA03001752A (es) Uso de la combinacion de salmeterol y propionato de fluticasona.
WO2002007672A3 (en) A medicinal aerosol formulation
ATE286716T1 (de) Pharmazeutische formulierungen enthaltend salmeterol
CA2446562A1 (en) Pharmaceutical formulation of fluticasone propionate
AU2003300230A1 (en) Dosing aerosols containing lecithin as a surface-active substance

Legal Events

Date Code Title Description
8363 Opposition against the patent